Invivyd Submits Request for Emergency Use Authorization (EUA) to US FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
Portfolio Pulse from Benzinga Newsdesk
Invivyd, Inc. (NASDAQ:IVVD) has submitted a request for Emergency Use Authorization (EUA) to the U.S. FDA for its monoclonal antibody candidate VYD222, aimed at preventing COVID-19 in immunocompromised individuals. The submission is supported by positive results from the CANOPY Phase 3 trial and ongoing in vitro activity against variants like JN.1.
January 03, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Invivyd has applied for EUA from the FDA for VYD222, which could prevent COVID-19 in immunocompromised adults and adolescents, based on positive Phase 3 trial results.
The submission for EUA by Invivyd is a significant regulatory milestone that could lead to increased investor confidence and potential stock price appreciation in the short term. Positive clinical trial results typically have a favorable impact on biopharmaceutical stocks, especially when they concern high-demand areas such as COVID-19 prevention. However, the actual impact will depend on the FDA's decision and market perception of the drug's potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100